We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.8%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.57B
AUM Growth
+$1.06B
Cap. Flow
+$745M
Cap. Flow %
7.79%
Top 10 Hldgs %
36.3%
Holding
159
New
27
Increased
34
Reduced
20
Closed
32

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$202M
2
COO icon
Cooper Companies
COO
+$180M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.3M
4
SHPG
Shire pic
SHPG
+$77.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$75.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$240M
2
VTRS icon
Viatris
VTRS
+$184M
3
AGN
Allergan Inc
AGN
+$107M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$89.3M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$43.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0.07%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$125B
$152M 1.58%
1,350,000
+822,000
+156% +$78.3M
ESRX
27
DELISTED
Express Scripts Holding Company
ESRX
$148M 1.55%
2,098,000
+19,000
+0.9% +$1.35M
HNT
28
DELISTED
HEALTH NET INC
HNT
$142M 1.48%
3,070,400
+195,000
+7% +$8.66M
MCK icon
29
McKesson
MCK
$106B
$138M 1.44%
708,000
+48,000
+7% +$9.24M
REGN icon
30
Regeneron Pharmaceuticals
REGN
$73B
$133M 1.39%
369,600
+43,000
+13% +$14.4M
ZBH icon
31
Zimmer Biomet
ZBH
$18.7B
$127M 1.32%
1,297,491
+83,430
+7% +$8.21M
MOH icon
32
Molina Healthcare
MOH
$10.6B
$116M 1.21%
2,737,900
+175,000
+7% +$7.74M
TRNX
33
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$115M 1.2%
4,805,000
+731,200
+18% +$16.3M
NBIX icon
34
Neurocrine Biosciences
NBIX
$18.2B
$90.8M 0.95%
5,793,600
+1,117,900
+24% +$16.7M
SYK icon
35
Stryker
SYK
$135B
$81M 0.85%
1,002,600
+8,000
+0.8% +$658K
PFE icon
36
Pfizer
PFE
$144B
$79M 0.82%
2,814,180
-1,488,248
-35% -$41.8M
ARWR icon
37
Arrowhead Research
ARWR
$12.1B
$76.5M 0.8%
5,178,200
+220,400
+4% +$3.01M
WMGI
38
DELISTED
Wright Medical Group Inc
WMGI
$74.1M 0.77%
+2,444,000
New +$75.3M
PODD icon
39
Insulet
PODD
$11.9B
$72M 0.75%
1,953,000
– –
SPY icon
40
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$775B
$69M 0.72%
350,000
– –
NPSP
41
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$68M 0.71%
2,616,000
+2,065,800
+375% +$59.3M
INFI
42
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$63.6M 0.66%
4,736,900
– –
STJ
43
DELISTED
St Jude Medical
STJ
$61.5M 0.64%
1,023,600
-640,000
-38% -$41.8M
OTIC
44
DELISTED
Otonomy, Inc.
OTIC
$54.2M 0.57%
+2,256,398
New +$44.6M
AFFX
45
DELISTED
Affymetrix Inc
AFFX
$52.4M 0.55%
6,568,000
– –
ALXN
46
DELISTED
Alexion Pharmaceuticals
ALXN
$51.7M 0.54%
312,000
– –
LAB icon
47
Standard BioTools
LAB
$325M
$51.5M 0.54%
2,100,200
+238,000
+13% +$6.69M
PBYI icon
48
Puma Biotechnology
PBYI
$398M
$50.8M 0.53%
212,900
-5,200
-2% -$1.07M
JNJ icon
49
Johnson & Johnson
JNJ
$646B
$45.1M 0.47%
423,000
-59,000
-12% -$6.12M
OSUR icon
50
OraSure Technologies
OSUR
$275M
$38.8M 0.41%
5,372,000
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2014 Portfolio in Review

As of Q3 2014, OrbiMed held 159 positions worth $9.57B, up 12% from $8.52B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed deployed $745M of net new capital in Q3 2014, opening 27 new positions and adding to 34 existing holdings. Its largest new stake was Cooper Companies: 4,570,800 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Viatris, an estimated $184M trimmed.

  • OrbiMed's largest Q3 2014 buy was Cooper Companies: 4,570,800 shares worth $178M.
  • OrbiMed added most to Allergan plc in Q3 2014, an estimated $202M increase.
  • OrbiMed's biggest Q3 2014 reduction was Viatris, cutting an estimated $184M.
  • OrbiMed fully exited INTERMUNE INC in Q3 2014, selling an estimated $240M.
  • OrbiMed's ten largest holdings make up 36% of its $9.57B portfolio in Q3 2014.
  • OrbiMed opened 27 new positions and closed 32 in Q3 2014.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $9.57B.

Based on OrbiMed's 13F filing for Q3 2014, filed 14 Nov 2014.